Welner S A, De Montigny C, Desroches J, Desjardins P, Suranyi-Cadotte B E
Douglas Hospital Research Centre, Montreal, Quebec, Canada.
Synapse. 1989;4(4):347-52. doi: 10.1002/syn.890040410.
There is growing evidence that the serotonergic (5-HT) system is involved in the pathogenesis and treatment of major depression. The 5-HT receptor subtype involved in the enhancing effect of antidepressant treatments, however, has not been identified. The present study was undertaken to quantify 5-HT1A sites in the rat brain by autoradiography and membrane binding, using the selective ligand [3H]8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT), following long-term antidepressant treatment. Following a 21-day treatment with amitriptyline (10 mg/kg/day), there was a significant increase of [3H]8-OH-DPAT binding measured by autoradiography in the dorsal hippocampus, but there was no change in the nucleus raphe dorsalis; whole brain membrane binding revealed an increase in the number of binding sites, with no change in the affinity for [3H]8-OH-DPAT. Conversely, fluoxetine (10 mg/kg/day), a selective blocker of 5-HT reuptake, and gepirone (10 mg/kg/day), a 5-HT1A agonist, both administered for 21 days, significantly reduced [3H]8-OH-DPAT binding measured by autoradiography in the nucleus raphe dorsalis without altering hippocampal binding sites. The control active treatment with diazepam (2 mg/kg/day) did not alter [3H]8-OH-DPAT binding in the hippocampus or in the nucleus raphe dorsalis. All groups were compared to a 21-day vehicle-treated control group. These results are fully consistent with previous electrophysiological and behavioral studies and suggest that alterations of 5-HT1A receptors might underlie the enhancement of 5-HT neurotransmission by antidepressant treatments.
越来越多的证据表明,血清素能(5-羟色胺,5-HT)系统参与了重度抑郁症的发病机制和治疗。然而,抗抑郁治疗增强作用所涉及的5-HT受体亚型尚未明确。本研究旨在通过放射自显影和膜结合法,使用选择性配体[3H]8-羟基-N,N-二丙基-2-氨基四氢萘(8-OH-DPAT),对长期接受抗抑郁治疗后的大鼠脑内5-HT1A位点进行定量分析。用阿米替林(10毫克/千克/天)进行21天治疗后,放射自显影法测得背侧海马体中[3H]8-OH-DPAT结合显著增加,但中缝背核无变化;全脑膜结合显示结合位点数量增加,对[3H]8-OH-DPAT的亲和力无变化。相反,氟西汀(10毫克/千克/天,一种5-HT再摄取选择性阻滞剂)和吉哌隆(10毫克/千克/天,一种5-HT1A激动剂)均给药21天,放射自显影法测得中缝背核中[3H]8-OH-DPAT结合显著减少,而海马体结合位点未改变。地西泮(2毫克/千克/天)作为对照活性治疗,未改变海马体或中缝背核中[3H]8-OH-DPAT结合。所有组均与接受21天赋形剂治疗的对照组进行比较。这些结果与先前的电生理和行为学研究完全一致,表明5-HT1A受体的改变可能是抗抑郁治疗增强5-HT神经传递的基础。